ScholarIQanswers from OpenAlex

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

PaperCitations, authors & open-access status

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial have?

ScholarIQcitation count

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial has 545 citations in the OpenAlex counts ScholarIQ stores.

When was Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial published?

ScholarIQyear

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial has 2012 year in the ScholarIQ index.

What is the open-access status of Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial?

ScholarIQoa status

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial has green oa status in the ScholarIQ index.

What is the DOI of Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial?

ScholarIQdoi

The DOI for Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial is on the source record.

What is the PMID of Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial?

ScholarIQpmid

The PMID for Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial is on the source record.

What is the OpenAlex record for Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial?

ScholarIQopenalex

The OpenAlex for Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial